Veracyte, Inc.
VCYT
Rangering i aksjer
#4414
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aksjekurs
$43.77
Sist synkronisert: 2026-10-19
Markedsverdi
$3.52B
Endring (1 dag)
1.51%
Endring (1 år)
19.43%
Land
US
Handel Veracyte, Inc. (VCYT)
Kategori
Healthcare
Utbyttehistorikk for Veracyte, Inc. (VCYT)
Veracyte, Inc. (aksjesymbol: VCYT) har gitt totalt 0 utbyttebetalinger.
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Summen av alle utbytter (justert for aksjesplitt): 0.00
Utbytteavkastning (TTM): 0
Utbyttebetalinger for Veracyte, Inc. (VCYT) fra 2026 til 2026
Årlige utbyttebetalinger
| År | Utbytte (justert for aksjesplitt) | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Liste over alle utbyttebetalinger
| År | Utbytte | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Utbyttebetalinger for lignende selskaper eller konkurrenter
| Selskap | Antall utbyttebetalinger | Land |
|---|---|---|
| 60.00% |
US
|
|
| 134.00% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
CN
|
|
| 58.00% |
US
|
